Dr Reddy’s Joins Hands With Gland Pharma To Market 8 ANDAs In U.S.
The deal provides a boost to Dr Reddy’s injectable business in the U.S.
Dr Reddy's Laboratories Ltd. entered into a collaboration with Gland Pharma to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs) in the U.S. market.
Gland Pharma is a Hyderabad-based developer and manufacturer of sterile dosage forms.
The portfolio is a mix of filed ANDAs pending approval by the United States Food and Drug Administration (USFDA), applications that will be filed imminently, and comprised of generic injectables administered in hospitals and clinics in America, Dr. Reddy's said in a statement.
Our strengths, combined with Gland’s track record of manufacturing and operational excellence, will help bring affordable medications within reach of patients and complement our speciality injectables offering in the short-to-medium term.Alok Sonig, Executive Vice President and Head of North America, Dr Reddy’s Laboratories, Said In An Exchange Filling.
Dr Reddy's is developing its injectable business in the U.S. and recently launched Paricalcitol injection, a therapeutic equivalent generic version of Zemplar there.
Shares of Dr Reddy’s Laboratories rose as much as 1.44 percent in trade to Rs 3,268.